candesartan cilexetil has been researched along with angiotensin iii in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Inada, Y; Nishikawa, K; Noda, M; Ojima, M; Sanada, T; Shibouta, Y; Wada, T | 1 |
| Inada, Y; Kohara, Y; Kubo, K; Naka, T; Nishikawa, K; Noda, M; Ojima, M; Sanada, T; Shibouta, Y; Wada, T | 1 |
| Champion, HC; Kadowitz, PJ; Lambert, DG | 1 |
| Inada, Y; Nishikawa, K; Ojima, M; Sanada, T; Shibouta, Y; Wada, T | 1 |
4 other study(ies) available for candesartan cilexetil and angiotensin iii
| Article | Year |
|---|---|
Effect of an angiotensin II receptor antagonist, CV-11974, and its prodrug, TCV-116, on production of aldosterone.
Topics: Administration, Oral; Adrenocorticotropic Hormone; Aldosterone; Angiotensin II; Angiotensin III; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Cells, Cultured; Corticosterone; Hypertension; Imidazoles; Infusions, Intravenous; Male; Pyridines; Rabbits; Rats; Rats, Inbred SHR; Rats, Wistar; Tetrazoles; Zona Glomerulosa | 1994 |
Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethy
Topics: Adrenal Cortex; Angiotensin II; Angiotensin III; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cattle; Imidazoles; In Vitro Techniques; Iodine Radioisotopes; Kinetics; Losartan; Male; Muscle Contraction; Muscle, Smooth, Vascular; Prodrugs; Protein Binding; Rabbits; Rats; Rats, Sprague-Dawley; Substrate Specificity; Tetrazoles | 1993 |
Inhibitory effects of candesartan on responses to angiotensin peptides in the hindquarters vascular bed of the cat.
Topics: Angiotensin II; Angiotensin III; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cats; Dose-Response Relationship, Drug; Female; Hindlimb; Male; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles; Vasoconstriction | 1998 |
Comparison of the antihypertensive effects of the new angiotensin II (AT1) receptor antagonist candesartan cilexetil (TCV-116) and the angiotensin converting enzyme inhibitor enalapril in rats.
Topics: Administration, Oral; Angiotensin I; Angiotensin II; Angiotensin III; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Bradykinin; Enalapril; Enzyme Activation; Hypertension, Renal; Male; Peptidyl-Dipeptidase A; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renal Artery; Surgical Instruments; Tetrazoles; Vasoconstrictor Agents | 1996 |